+ Watch DCTH
on My Watchlist
The Company is a development stage Company.
Delcath is a good example of the dangers of picking a beaten down stock because it just has to go back up someday. I tried it twice with Delcath and took big losses before I finally has some moderate success the third time around. The problem, as I've stated before, is that the cheap-looking stock gets cheaper while the S&P goes up, and the differential gets so wide that even the long-awaited spike on a positive catalyst can't come close to bridging the divide.I only escaped my third green thumb on Delcath with a positive score because I was browsing my watchlist and quick on the trigger when the announcement of Orphan Drug status for the melphalan Chemosat system for hepatocellular carcinoma came through. I knew the gains wouldn't hold because Delcath is a dying stock with a dead end product and pipeline, and everyone who follows biopharma with a clear mind knows it. All that remains is a trader's playing field trying to guess which direction the zombie will lurch until somebody finally puts a bullet through its brain. Hopefully for my CAPS score, I'm done giving in to the temptation to green thumb this one forever. I have a feeling, however, that a reverse split will give me many more opportunities to apply red thumbs.
Will pass FDA..
This stock will continue to grow will the anticipation of FDA approval.
PDUFA-date of June 14th. Run-up expected in May-2013. Expect run-up to $3.5+
upside potential unlimited when product benefits so many people and company is beaten down by the large drug companies. Delcath will be bought out by bms or pfizer in the near future
Cannot remember who I was following on this pick.
The PHP system they are developing will pass FDA approval and become the standard of care for organ chemotherapy treatment.
DCTH has a lot of cash for a development stage company. And unlike the run up in december to almost $12 per the NDA , this year they have exposure in Europe... could we then see a run up to $15-$16 before the next NDA in Sept 2011?? Something to think about...
Because the FDA did not squash the product but has unresolved questions about it that require clarification.
DCTH is awaiting NDA from the FDA. It has begun to run as a result and its chart looks extremely positive technically. They just disclosed a 5.08% Blackrock stake in FDA 13g filing. And if the CEO is correct with his believe of 15b market potential, this stock is worth many times its current value.
FDA approval very optimistic.
Delcath should get approval for melanoma mid-2011. The opportunity is much bigger for its PHP system though.
This is really a no brainer when you get past all of the rhetoric. They built a system that puts Chemo only into the organ/region with cancer instead of poisoning the whole patient.Once approved by the FDA in 2011 I predict a $50 share price.
Unique drug delivery system
Significant phase III results, high short interest will cause this to pop going into FDA approval
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions